ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Article Swipe
Michelle Wang
,
Shadera Slatter
,
Jesse Sussell
,
Chia-Wei Lin
,
Sarika Ogale
,
Debajyoti Datta
,
Atul J. Butte
,
Lyudmila Bazhenova
,
Vivek A. Rudrapatna
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1007/s11523-023-00973-7
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1007/s11523-023-00973-7
Related Topics
Concepts
Crizotinib
Alectinib
Medicine
Anaplastic lymphoma kinase
Internal medicine
Lung cancer
Oncology
Hazard ratio
Adverse effect
Ceritinib
Discontinuation
Retrospective cohort study
Malignant pleural effusion
Confidence interval
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1007/s11523-023-00973-7
- https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdf
- OA Status
- hybrid
- Cited By
- 15
- References
- 36
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4381469550
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4381469550Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s11523-023-00973-7Digital Object Identifier
- Title
-
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort StudyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-06-21Full publication date if available
- Authors
-
Michelle Wang, Shadera Slatter, Jesse Sussell, Chia-Wei Lin, Sarika Ogale, Debajyoti Datta, Atul J. Butte, Lyudmila Bazhenova, Vivek A. RudrapatnaList of authors in order
- Landing page
-
https://doi.org/10.1007/s11523-023-00973-7Publisher landing page
- PDF URL
-
https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdfDirect OA link when available
- Concepts
-
Crizotinib, Alectinib, Medicine, Anaplastic lymphoma kinase, Internal medicine, Lung cancer, Oncology, Hazard ratio, Adverse effect, Ceritinib, Discontinuation, Retrospective cohort study, Malignant pleural effusion, Confidence intervalTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
15Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 12, 2024: 2, 2023: 1Per-year citation counts (last 5 years)
- References (count)
-
36Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4381469550 |
|---|---|
| doi | https://doi.org/10.1007/s11523-023-00973-7 |
| ids.doi | https://doi.org/10.1007/s11523-023-00973-7 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/37341856 |
| ids.openalex | https://openalex.org/W4381469550 |
| fwci | 5.06062478 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000328 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adult |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D006801 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Humans |
| mesh[2].qualifier_ui | Q000473 |
| mesh[2].descriptor_ui | D002289 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | pathology |
| mesh[2].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[3].qualifier_ui | Q000494 |
| mesh[3].descriptor_ui | D000077547 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | pharmacology |
| mesh[3].descriptor_name | Crizotinib |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D000077547 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Crizotinib |
| mesh[5].qualifier_ui | Q000473 |
| mesh[5].descriptor_ui | D008175 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pathology |
| mesh[5].descriptor_name | Lung Neoplasms |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D012189 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Retrospective Studies |
| mesh[7].qualifier_ui | Q000139 |
| mesh[7].descriptor_ui | D001919 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | chemically induced |
| mesh[7].descriptor_name | Bradycardia |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D001919 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Bradycardia |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D000077548 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Anaplastic Lymphoma Kinase |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D047428 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Protein Kinase Inhibitors |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D011505 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Protein-Tyrosine Kinases |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000328 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Adult |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006801 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Humans |
| mesh[14].qualifier_ui | Q000473 |
| mesh[14].descriptor_ui | D002289 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | pathology |
| mesh[14].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[15].qualifier_ui | Q000494 |
| mesh[15].descriptor_ui | D000077547 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | pharmacology |
| mesh[15].descriptor_name | Crizotinib |
| mesh[16].qualifier_ui | Q000627 |
| mesh[16].descriptor_ui | D000077547 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | therapeutic use |
| mesh[16].descriptor_name | Crizotinib |
| mesh[17].qualifier_ui | Q000473 |
| mesh[17].descriptor_ui | D008175 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | pathology |
| mesh[17].descriptor_name | Lung Neoplasms |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D012189 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Retrospective Studies |
| mesh[19].qualifier_ui | Q000139 |
| mesh[19].descriptor_ui | D001919 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | chemically induced |
| mesh[19].descriptor_name | Bradycardia |
| mesh[20].qualifier_ui | Q000188 |
| mesh[20].descriptor_ui | D001919 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | drug therapy |
| mesh[20].descriptor_name | Bradycardia |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D000077548 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Anaplastic Lymphoma Kinase |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D047428 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Protein Kinase Inhibitors |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D011505 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Protein-Tyrosine Kinases |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D000328 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Adult |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D006801 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Humans |
| mesh[26].qualifier_ui | Q000473 |
| mesh[26].descriptor_ui | D002289 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | pathology |
| mesh[26].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[27].qualifier_ui | Q000494 |
| mesh[27].descriptor_ui | D000077547 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | pharmacology |
| mesh[27].descriptor_name | Crizotinib |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000077547 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Crizotinib |
| mesh[29].qualifier_ui | Q000473 |
| mesh[29].descriptor_ui | D008175 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | pathology |
| mesh[29].descriptor_name | Lung Neoplasms |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D012189 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Retrospective Studies |
| mesh[31].qualifier_ui | Q000139 |
| mesh[31].descriptor_ui | D001919 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | chemically induced |
| mesh[31].descriptor_name | Bradycardia |
| mesh[32].qualifier_ui | Q000188 |
| mesh[32].descriptor_ui | D001919 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | drug therapy |
| mesh[32].descriptor_name | Bradycardia |
| mesh[33].qualifier_ui | Q000627 |
| mesh[33].descriptor_ui | D000077548 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | therapeutic use |
| mesh[33].descriptor_name | Anaplastic Lymphoma Kinase |
| mesh[34].qualifier_ui | Q000627 |
| mesh[34].descriptor_ui | D047428 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | therapeutic use |
| mesh[34].descriptor_name | Protein Kinase Inhibitors |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D011505 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Protein-Tyrosine Kinases |
| type | article |
| title | ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study |
| biblio.issue | 4 |
| biblio.volume | 18 |
| biblio.last_page | 583 |
| biblio.first_page | 571 |
| grants[0].funder | https://openalex.org/F4320332161 |
| grants[0].award_id | 5T32GM007175-43 |
| grants[0].funder_display_name | National Institutes of Health |
| grants[1].funder | https://openalex.org/F4320332193 |
| grants[1].award_id | |
| grants[1].funder_display_name | Genentech |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T12334 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9984999895095825 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Lung Cancer Research Studies |
| topics[2].id | https://openalex.org/T10202 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9958000183105469 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Lung Cancer Diagnosis and Treatment |
| funders[0].id | https://openalex.org/F4320332161 |
| funders[0].ror | https://ror.org/01cwqze88 |
| funders[0].display_name | National Institutes of Health |
| funders[1].id | https://openalex.org/F4320332193 |
| funders[1].ror | https://ror.org/04gndp242 |
| funders[1].display_name | Genentech |
| is_xpac | False |
| apc_list.value | 3390 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4390 |
| apc_paid.value | 3390 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 4390 |
| concepts[0].id | https://openalex.org/C2779422266 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9273431897163391 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q5186964 |
| concepts[0].display_name | Crizotinib |
| concepts[1].id | https://openalex.org/C2779220645 |
| concepts[1].level | 5 |
| concepts[1].score | 0.9011359214782715 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q21099132 |
| concepts[1].display_name | Alectinib |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.8922997117042542 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C117643217 |
| concepts[3].level | 4 |
| concepts[3].score | 0.6852603554725647 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q17824987 |
| concepts[3].display_name | Anaplastic lymphoma kinase |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6463459730148315 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2776256026 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5664394497871399 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[5].display_name | Lung cancer |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5590523481369019 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C207103383 |
| concepts[7].level | 3 |
| concepts[7].score | 0.502450704574585 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[7].display_name | Hazard ratio |
| concepts[8].id | https://openalex.org/C197934379 |
| concepts[8].level | 2 |
| concepts[8].score | 0.48486122488975525 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[8].display_name | Adverse effect |
| concepts[9].id | https://openalex.org/C2779750558 |
| concepts[9].level | 5 |
| concepts[9].score | 0.45813632011413574 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q21011233 |
| concepts[9].display_name | Ceritinib |
| concepts[10].id | https://openalex.org/C2778715236 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4544459283351898 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q55622662 |
| concepts[10].display_name | Discontinuation |
| concepts[11].id | https://openalex.org/C167135981 |
| concepts[11].level | 2 |
| concepts[11].score | 0.4130946695804596 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[11].display_name | Retrospective cohort study |
| concepts[12].id | https://openalex.org/C2776232967 |
| concepts[12].level | 3 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q6743514 |
| concepts[12].display_name | Malignant pleural effusion |
| concepts[13].id | https://openalex.org/C44249647 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[13].display_name | Confidence interval |
| keywords[0].id | https://openalex.org/keywords/crizotinib |
| keywords[0].score | 0.9273431897163391 |
| keywords[0].display_name | Crizotinib |
| keywords[1].id | https://openalex.org/keywords/alectinib |
| keywords[1].score | 0.9011359214782715 |
| keywords[1].display_name | Alectinib |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.8922997117042542 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/anaplastic-lymphoma-kinase |
| keywords[3].score | 0.6852603554725647 |
| keywords[3].display_name | Anaplastic lymphoma kinase |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6463459730148315 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/lung-cancer |
| keywords[5].score | 0.5664394497871399 |
| keywords[5].display_name | Lung cancer |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.5590523481369019 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/hazard-ratio |
| keywords[7].score | 0.502450704574585 |
| keywords[7].display_name | Hazard ratio |
| keywords[8].id | https://openalex.org/keywords/adverse-effect |
| keywords[8].score | 0.48486122488975525 |
| keywords[8].display_name | Adverse effect |
| keywords[9].id | https://openalex.org/keywords/ceritinib |
| keywords[9].score | 0.45813632011413574 |
| keywords[9].display_name | Ceritinib |
| keywords[10].id | https://openalex.org/keywords/discontinuation |
| keywords[10].score | 0.4544459283351898 |
| keywords[10].display_name | Discontinuation |
| keywords[11].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[11].score | 0.4130946695804596 |
| keywords[11].display_name | Retrospective cohort study |
| language | en |
| locations[0].id | doi:10.1007/s11523-023-00973-7 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S163958984 |
| locations[0].source.issn | 1776-2596, 1776-260X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1776-2596 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Targeted Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310320330 |
| locations[0].source.host_organization_name | Adis, Springer Healthcare |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320330 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Targeted Oncology |
| locations[0].landing_page_url | https://doi.org/10.1007/s11523-023-00973-7 |
| locations[1].id | pmid:37341856 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Targeted oncology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/37341856 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10345061 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | cc-by-nc |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10345061/pdf/11523_2023_Article_973.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Target Oncol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10345061 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5038826627 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3207-1490 |
| authorships[0].author.display_name | Michelle Wang |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[0].affiliations[0].raw_affiliation_string | Bakar Computational Health Sciences Institute, University of California San Francisco, UCSF Valley Tower, Box 2933 Room 21E, 490 Illinois Street, Floor 2, San Francisco, CA, 94143, USA |
| authorships[0].institutions[0].id | https://openalex.org/I180670191 |
| authorships[0].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | University of California, San Francisco |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Michelle Wang |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Bakar Computational Health Sciences Institute, University of California San Francisco, UCSF Valley Tower, Box 2933 Room 21E, 490 Illinois Street, Floor 2, San Francisco, CA, 94143, USA |
| authorships[1].author.id | https://openalex.org/A5033274345 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Shadera Slatter |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[1].affiliations[0].raw_affiliation_string | Bakar Computational Health Sciences Institute, University of California San Francisco, UCSF Valley Tower, Box 2933 Room 21E, 490 Illinois Street, Floor 2, San Francisco, CA, 94143, USA |
| authorships[1].institutions[0].id | https://openalex.org/I180670191 |
| authorships[1].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | University of California, San Francisco |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Shadera Slatter |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Bakar Computational Health Sciences Institute, University of California San Francisco, UCSF Valley Tower, Box 2933 Room 21E, 490 Illinois Street, Floor 2, San Francisco, CA, 94143, USA |
| authorships[2].author.id | https://openalex.org/A5026454069 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9713-8983 |
| authorships[2].author.display_name | Jesse Sussell |
| authorships[2].affiliations[0].raw_affiliation_string | Evidence for Access, Genentech Inc., South San Francisco, CA, USA |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Jesse Sussell |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Evidence for Access, Genentech Inc., South San Francisco, CA, USA |
| authorships[3].author.id | https://openalex.org/A5101059234 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Chia-Wei Lin |
| authorships[3].affiliations[0].raw_affiliation_string | Evidence for Access, Genentech Inc., South San Francisco, CA, USA |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Chia-Wei Lin |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Evidence for Access, Genentech Inc., South San Francisco, CA, USA |
| authorships[4].author.id | https://openalex.org/A5051465568 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Sarika Ogale |
| authorships[4].affiliations[0].raw_affiliation_string | Evidence for Access, Genentech Inc., South San Francisco, CA, USA |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sarika Ogale |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Evidence for Access, Genentech Inc., South San Francisco, CA, USA |
| authorships[5].author.id | https://openalex.org/A5068830481 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3084-7603 |
| authorships[5].author.display_name | Debajyoti Datta |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[5].affiliations[0].raw_affiliation_string | Bakar Computational Health Sciences Institute, University of California San Francisco, UCSF Valley Tower, Box 2933 Room 21E, 490 Illinois Street, Floor 2, San Francisco, CA, 94143, USA |
| authorships[5].institutions[0].id | https://openalex.org/I180670191 |
| authorships[5].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | University of California, San Francisco |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Debajyoti Datta |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Bakar Computational Health Sciences Institute, University of California San Francisco, UCSF Valley Tower, Box 2933 Room 21E, 490 Illinois Street, Floor 2, San Francisco, CA, 94143, USA |
| authorships[6].author.id | https://openalex.org/A5036068985 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-7433-2740 |
| authorships[6].author.display_name | Atul J. Butte |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA |
| authorships[6].institutions[0].id | https://openalex.org/I180670191 |
| authorships[6].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | University of California, San Francisco |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Atul J. Butte |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA |
| authorships[7].author.id | https://openalex.org/A5036466135 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8764-4359 |
| authorships[7].author.display_name | Lyudmila Bazhenova |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I36258959 |
| authorships[7].affiliations[0].raw_affiliation_string | Moores Cancer Center, University of California San Diego, La Jolla, CA, USA |
| authorships[7].institutions[0].id | https://openalex.org/I36258959 |
| authorships[7].institutions[0].ror | https://ror.org/0168r3w48 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I36258959 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | University of California, San Diego |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Lyudmila Bazhenova |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Moores Cancer Center, University of California San Diego, La Jolla, CA, USA |
| authorships[8].author.id | https://openalex.org/A5073538344 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-1789-3004 |
| authorships[8].author.display_name | Vivek A. Rudrapatna |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[8].affiliations[0].raw_affiliation_string | Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA |
| authorships[8].institutions[0].id | https://openalex.org/I180670191 |
| authorships[8].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | University of California, San Francisco |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Vivek A. Rudrapatna |
| authorships[8].is_corresponding | True |
| authorships[8].raw_affiliation_strings | Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W2148613928, https://openalex.org/W4242233337, https://openalex.org/W2533300620, https://openalex.org/W2570122045, https://openalex.org/W2917656567, https://openalex.org/W2969411178, https://openalex.org/W2940077771, https://openalex.org/W2319183095, https://openalex.org/W2560284840, https://openalex.org/W2753977688 |
| cited_by_count | 15 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 12 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1007/s11523-023-00973-7 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S163958984 |
| best_oa_location.source.issn | 1776-2596, 1776-260X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1776-2596 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Targeted Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320330 |
| best_oa_location.source.host_organization_name | Adis, Springer Healthcare |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Targeted Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s11523-023-00973-7 |
| primary_location.id | doi:10.1007/s11523-023-00973-7 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S163958984 |
| primary_location.source.issn | 1776-2596, 1776-260X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1776-2596 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Targeted Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310320330 |
| primary_location.source.host_organization_name | Adis, Springer Healthcare |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320330 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s11523-023-00973-7.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Targeted Oncology |
| primary_location.landing_page_url | https://doi.org/10.1007/s11523-023-00973-7 |
| publication_date | 2023-06-21 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W3128646645, https://openalex.org/W4211059596, https://openalex.org/W2055402151, https://openalex.org/W2168691181, https://openalex.org/W2061278019, https://openalex.org/W2172010139, https://openalex.org/W2759298856, https://openalex.org/W2050368996, https://openalex.org/W2094903176, https://openalex.org/W2839057355, https://openalex.org/W2785110924, https://openalex.org/W2050249255, https://openalex.org/W2624310346, https://openalex.org/W3101089668, https://openalex.org/W2894476389, https://openalex.org/W2295354328, https://openalex.org/W3070570721, https://openalex.org/W3032595234, https://openalex.org/W4206105531, https://openalex.org/W3045494105, https://openalex.org/W3028890726, https://openalex.org/W2969218718, https://openalex.org/W3178843879, https://openalex.org/W2085752173, https://openalex.org/W2810551427, https://openalex.org/W4312681151, https://openalex.org/W2967365762, https://openalex.org/W2952455110, https://openalex.org/W2576536258, https://openalex.org/W3022131485, https://openalex.org/W3198449529, https://openalex.org/W4281553053, https://openalex.org/W3170473231, https://openalex.org/W2939690516, https://openalex.org/W4295828446, https://openalex.org/W4200356483 |
| referenced_works_count | 36 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5073538344 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I180670191 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.95134339 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |